TABLE 2

Activity of cefepime-tazobactam combination and comparator agents tested against bacterial isolates collected worldwide in 2014

Organism and antimicrobial agentMIC50 (μg/ml)MIC90 (μg/ml)% susceptible by use of CLSI/EUCAST breakpoint criteriaa (no. of isolates)
United StatesEuropeLatin AmericaAPACdChinaAll regions
Enterobacteriaceae(2,466)(2,351)(466)(693)(243)(6,219)
    Cefepime-tazobactam (tazobactam at fixed 8 μg/ml)≤0.030.2598.3/97.6b95.8/94.3b94.4/91.4b98.7/97.8b93.8/92.6b96.9/95.7b
    Cefepime-tazobactam (tazobactam at fixed 4 μg/ml)0.060.598.1/97.1b94.7/93.2b92.9/90.3b98.1/96.5b93.4/91.8b96.2/94.9b
    Cefepime0.061692.2/90.481.1/79.264.8/63.386.3/83.860.5/56.484.0/82.1
    Ceftazidime0.25>1688.9/86.478.4/74.665.9/60.382.5/78.268.7/58.881.7/78.0
    Ceftriaxone≤0.06>884.5/84.572.1/72.158.4/58.477.3/77.349.0/49.075.7/78.0
    Piperacillin-tazobactam23292.0/88.984.2/79.582.6/78.889.2/85.084.6/79.387.7/83.8
    Meropenem0.030.0697.9/98.295.5/95.994.8/95.598.6/98.794.2/94.296.7/97.0
    Levofloxacin≤0.12>884.4/83.178.0/75.963.5/62.782.7/81.163.2/61.279.4/77.8
    Gentamicin≤1490.1/88.485.3/84.172.7/71.984.6/84.363.0/62.685.3/84.1
P. aeruginosa(390)(391)(109)(197)(84)(1,171)
    Cefepime-tazobactam (tazobactam at fixed 8 μg/ml)21685.9c79.8c79.8c85.8c73.8c82.4b
    Cefepime-tazobactam (tazobactam at fixed 4 μg/ml)21686.2c78.5c78.9c85.8c73.8c82.0b
    Cefepime21684.4/84.478.3/78.377.1/77.184.8/84.872.6/72.680.9/80.9
    Ceftazidime2>1687.2/87.273.1/73.170.6/70.679.7/79.770.2/70.278.5/78.5
    Piperacillin-tazobactam4>6486.2/86.274.7/74.776.1/76.181.7/81.766.7/66.779.2/79.2
    Meropenem0.5885.6/85.673.9/73.975.2/75.283.2/53.269.0/69.079.2/79.2
    Levofloxacin0.5>479.0/67.771.1/63.767.0/59.680.7/72.676.2/67.975.3/66.4
    Amikacin2897.2/92.891.0/86.790.8/89.994.4/91.991.7/88.193.7/90.0
Acinetobacter spp.(152)(184)(72)(93)(90)(591)
    Cefepime-tazobactam (tazobactam at fixed 8 μg/ml)64>6453.9c18.5c9.7c18.3c15.6c26.1b
    Cefepime-tazobactam (tazobactam at fixed 4 μg/ml)64>6453.3c17.4c8.3c18.3c15.6c25.9b
    Cefepime64>6446.7/—16.3/—6.9/—17.2/—14.4/—22.8/—
    Ceftazidime>32>3254.6/—17.4/—9.7/—19.4/—14.4/—25.9/—
    Piperacillin-tazobactam>64>6453.9/—19.6/—6.9/—17.2/—12.4/—25.4/—
    Ampicillin-sulbactam32>3263.6/—24.5/—18.1/—16.1/—15.6/—31.0/—
    Meropenem>32>3256.6/56.626.1/26.111.1/11.117.2/17.216.7/16.729.3/—
    Levofloxacin>4>453.3/52.618.5/17.411.1/11.118.3/18.315.6/15.626.1/25.4
    Amikacin>32>3278.1/74.828.8/26.613.9/12.530.1/26.921.1/18.938.6/36.1
  • a Unless indicated otherwise, the data are based on the criteria published by CLSI (7) and EUCAST (12). For cefepime-tazobactam, only CLSI criteria were applied. — indicates that breakpoints have not been established.

  • b Percentage inhibited by ≤8 μg/ml cefepime/≤2 μg/ml cefepime, according to the CLSI breakpoint criteria for cefepime susceptibility for high and low dosages (2 g every 8 h and 1 g every 12 h, respectively), as published in CLSI document M100-S26 (7).

  • c Percentage inhibited at ≤8 μg/ml, according to the CLSI breakpoint for cefepime susceptibility published by the CLSI (7) and EUCAST (12) (P. aeruginosa only).

  • d APAC, Asia-Pacific region excluding China.